公司资料
NuCana plc 股价、新闻与催化剂
- 股票代码:
- NCNA
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United Kingdom
股票表现
1.52 USD (-0.65%)
收盘价
最后更新: 2026年8月21日
8.62M USD
市值
股价为何变动
As of Aug 21, 2026, NCNA closed down 0.65% at $1.52. No new same-company headline was identified in the current news window.
公司概览
ProTide Oncology Company
NuCana applies its ProTide chemistry platform to transform nucleoside analogs into medicines designed to generate higher concentrations of active anticancer metabolites inside tumor cells.
NUC-7738
NUC-7738 is a ProTide that disrupts RNA polyadenylation and affects multiple components of the tumor microenvironment. It is being evaluated with pembrolizumab in PD-1-inhibitor-resistant melanoma.
NUC-3373
NUC-3373 is a targeted thymidylate-synthase inhibitor designed to overcome pharmacologic limitations of established fluoropyrimidine therapies.
Combination Development
NuCana is evaluating tumor types and drug combinations that could support future registrational strategies for both NUC-7738 and NUC-3373.
未来催化剂
- Final data from the Phase 2 NuTide:701 expansion study of NUC-7738 in melanoma during 2026.
- FDA guidance on a potential registrational strategy for NUC-7738 in melanoma during 2026.
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。